Stocktradesmoon
Sep 27, 8:41 PM
$ABCL
October 1st is not just another date on the calendar.
ABCL635 Phase 2 data will be presented at the IMS World Congress on Menopause.
We already know the topline results were positive.
Now we get to see more of the actual data.
For me, this is exactly why I own
$ABCL
Not for tomorrow.
Not for a quick trade.
Not because I expect every catalyst to send the stock +20%.
I own it because if AbCellera proves it can repeatedly take internally developed antibodies from discovery to meaningful clinical assets, the entire way the market values this company can change.
ABCL635 is one test of that thesis.
October 1st matters. 👀
But the story is much BIGGER than October 1st.
I’m holding. Let’s see the data.
0 replies